Company Overview
Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Currently focused on cancer and monogenic diseases, Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-1365, a first-in-class selective small-molecule inhibitor of CDK7 in a Phase 1 trial in ovarian and breast cancer patients. Syros also has multiple preclinical and discovery programs in oncology and sickle cell disease, including SY-5609, a highly selective and potent oral CDK7 inhibitor.

Syros to Present at 2019 Wedbush PacGrow Healthcare Conference
Aug 6 2019, 4:01 PM EDT

Syros Reports Second Quarter 2019 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Aug 1 2019, 7:31 AM EDT

Stock Overview
Symbol SYRS
Exchange Nasdaq
Market Cap 373.03m
Last Price $8.79
52-Week Range $5.17 - $11.93
10/11/2019 04:00 PM EDT

Investor Relations
Stern Investor Relations, Inc.
Hannah Deresiewicz
hannahd@sternir.com

Disclaimer
Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.